O-6 The novel regimen of tremelimumab in combination with durvalumab provides a favorable safety profile and clinical activity for patients with advanced hepatocellular carcinoma

Robin Kate Kelley; Masatoshi Kudo; William Proctor Harris; Masafumi Ikeda; Takuji Okusaka; Yoon‐Koo Kang; Shukui Qin; David Tai; H. Lim; Thomas Yau; Wei Peng Yong; Ann‐Lii Cheng; Antonio Gasbarrini; Filippo de Braud; Jordi Bruix; Mitesh J. Borad; Nathan Standifer; Peng He; Alejandra Negro; Gordana Vlahovic; Bruno Sangro; Ghassan K. Abou‐Alfa

doi:10.1016/j.annonc.2020.04.059

Article2020

Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).

Robin Kate Kelley, Bruno Sangro, William Proctor Harris, Masafumi Ikeda, Takuji Okusaka, Yoon‐Koo Kang, Shukui Qin, Wai Meng David Tai, Ho Yeong Lim, Thomas Yau, Wei Peng Yong, Ann‐Lii Cheng, Antonio Gasbarrini, Filippo de Braud, Jordi Bruix, Mitesh J. Borad, Philip He, Alejandra Negro, Masatoshi Kudo, Ghassan K. Abou‐Alfa

Editorial Material2022

Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma

Masatoshi Kudo

Article2025

Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study

Alba Sparacino, Gabriele Di Maria, Marco Vaccaro, Giuseppe Cabibbo, Calogero Cammà, María Reig, Robin Kate Kelley, Amit G. Singal, Ahmed O. Kaseb, Masatoshi Kudo, Lorenza Rimassa, David J. Pinato, Ciro Celsa, Tiziana Pressiani, Naoshi Nishida, Shadi Chamseddine, Ashwini Arvind, Michael Li, Marta Fortuny, Najib Ben Khaled, Massimo Iavarone, Hidenori Toyoda,

Article2016

Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC).

Ghassan K. Abou‐Alfa, Bruno Sangro, Michael A. Morse, Andrew X. Zhu, Richard D. Kim, Ann‐Lii Cheng, Masatoshi Kudo, Yoon‐Koo Kang, Stephen L. Chan, Joyce Antal, Jillian Boice, Feng Xiao, Shannon R. Morris, Johanna C. Bendell

Article2025

Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter Analysis

Tomomitsu Matono, Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Hiroki Nishikawa, Kazunari Tanaka, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Yuichi Koshiyama, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Hidenao Noritake,

O-6 The novel regimen of tremelimumab in combination with durvalumab provides a favorable safety profile and clinical activity for patients with advanced hepatocellular carcinoma

Discussion(0)

Related publications

Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).

Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma

Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study

Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC).

Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter Analysis